One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell CarcinomaThe CANTATA Randomized Clinical Trial
Nizar M. Tannir, MD; Neeraj Agarwal, MD; Camillo Porta, MD; et al.
doi : 10.1001/jamaoncol.2022.3511
October 2022, Vol 8, No. 10, Pages 1379-1520
Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated LiposarcomaA Phase 2 Study of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG)
Roberta Sanfilippo, MD; Richard L. Hayward; Jammbe Musoro; et al.
Assessment of Lung Cancer Risk Among Smokers for Whom Annual Screening Is Not Recommended
Charles Faselis, MD; Joel A. Nations, MD; Charity J. Morgan, PhD; et al.
Relapse Rates and Disease-Specific Mortality Following Procedures for Fertility Preservation at Time of Breast Cancer Diagnosis
Anna Marklund, MD, PhD; Tobias Lekberg, MD; Elham Hedayati, MD, PhD; et al.
Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive SystemThe TOPIC-NEC Phase 3 Randomized Clinical Trial
Chigusa Morizane, MD, PhD; Nozomu Machida, MD, PhD; Yoshitaka Honma, MD; et al.
Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal CancerSystematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials
Harry H. Yoon, MD, MHS; Zhaohui Jin, MD; Oudom Kour, MS; et al.
Patterns of Practice and Improvements in Survival Among Patients With Stage 2/3 Rectal Cancer Treated With Trimodality Therapy
Hagen F. Kennecke, MD; Henry T. Bahnson, MPH; Bruce Lin, MD; et al.
Association Between Prostate-Specific Antigen Screening and Prostate Cancer Mortality Among Non-Hispanic Black and Non-Hispanic White US Veterans
Michael V. Sherer, MD; Edmund M. Qiao, BS; Nikhil V. Kotha, BS; et al.
Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19
Sabine Haggenburg, MD; Quincy Hofsink, MD; Birgit I. Lissenberg-Witte, PhD; et al.
Handling Informative Premature Treatment or Study Discontinuation for Assessing Between-Group Differences in a Comparative Oncology Trial
Bo Huang, PhD; Ryan Sun, PhD; Brian Claggett, PhD; et al.
Postmarketing Colitis Cases Associated With Alpelisib Use Reported to the US Food and Drug Administration
Kathleen M. Sullivan, PharmD, BCOP; Graça M. Dores, MD, MPH; Afrouz Nayernama, PharmD; et al.
Association of Sociodemographic Characteristics With Survival Among Patients With Urachal Cancer in California From 1988 to 2019
David J. Benjamin, MD; Anshu Shrestha, PhD, MPH; Dimitra Fellman, BS; et al.
Reporting of Race and Hispanic Ethnicity in Breast Cancer Studies From the National Cancer Database
Jose G. Bazan, MD, MS; Samilia Obeng-Gyasi, MD; Mauricio E. Gamez, MD
World Health Organization 2021 Classification of Central Nervous System Tumors and Implications for Therapy for Adult-Type GliomasA Review
Tamar R. Berger, MD, PhD; Patrick Y. Wen, MD; Melanie Lang-Orsini, MD; et al.
Race and Ethnicity–Conscious Clinical Research Best Practices
Odeth Barrett-Campbell, MD; Maya DeGroote, MD; Frederick Lansigan, MD
Aspirin and the USPSTF—What About Cancer?
Andrew T. Chan, MD, MPH
The Implications of the Supreme Court Decision to Overturn Roe v Wade for Women With Pregnancy-Associated Cancers
Jordyn Silverstein; Katherine Van Loon, MD, MPH
Reforming Patient Cost Sharing for Cancer Medications in Medicare Part D
Thomas J. Hwang, MD; Aaron S. Kesselheim, MD, JD, MPH; Stacie B. Dusetzina, PhD
Glutaminase Inhibitors—Do They Have a Role in the Treatment of Metastatic Clear-Cell Renal Cell Carcinoma?
Janet E. Brown, MD
Optimizing Histology-Specific Clinical Trials in Soft-Tissue Sarcoma—Are We There Yet?
Christina L. Roland, MD, MS
A Lived Experience of Breast Cancer as a Scholar of Intersectionality
Kristi Tredway, PhD
Underrecognition of Symptoms During Breast Radiotherapy
Katie Fitzgerald Jones, MSN, APRN; Lakeshia Cousin, PhD, APRN; Salimah H. Meghani, PhD, RN, MBE, FAAN
Underrecognition of Symptoms During Breast Radiotherapy
Shijie Yang, MD; Xiequn Xu, MD
Underrecognition of Symptoms During Breast Radiotherapy—Reply
Reshma Jagsi, MD, DPhil; Kent A. Griffith, MS, MPH
Caution Regarding Assessment of Toxic Effects and Survival in Treatment De-escalation With Radiotherapy vs Transoral Surgery for Human Papillomavirus–Associated Oropharyngeal Cancer
Armando De Virgilio, MD, PhD; Andrea Costantino, MD; Giuseppe Spriano, MD
Caution Regarding Assessment of Toxic Effects and Survival in Treatment De-escalation With Radiotherapy vs Transoral Surgery for Human Papillomavirus–Associated Oropharyngeal Cancer
Vinidh Paleri, MBBS, MS; Christian Simon, MD; Philippe Gorphe, MD, MSc
Caution Regarding Assessment of Toxic Effects and Survival in Treatment De-escalation With Radiotherapy vs Transoral Surgery for Human Papillomavirus–Associated Oropharyngeal Cancer
Michael C. Topf, MD; F. Christopher Holsinger, MD; Mihir Patel, MD
Caution Regarding Assessment of Toxic Effects and Survival in Treatment De-escalation With Radiotherapy vs Transoral Surgery for Human Papillomavirus–Associated Oropharyngeal Cancer—Reply
David A. Palma, MD, PhD; Anthony C. Nichols, MD
SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US
Yung-Shuo Kao, MD; James Cheng-Chung Wei, MD, PhD; Chih-Jung Yeh, PhD
SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US
Binghao Zhao, MD, PhD; Yu Xia, MD; Wenbin Ma, MD
SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US
Renin Chang, MD; Hui-Yuan Chen, BS; Chih-Cheng Lai, MD
SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US—Reply
Rong Xu, PhD; Nathan A. Berger, MD
Analysis of Quality-of-Life Outcomes by Drug Class in Cancer Clinical Trials
Bellinda L. King-Kallimanis, PhD; Upal Basu-Roy, MPH, PhD; Sandra Nolte, PhD
Analysis of Quality-of-Life Outcomes by Drug Class in Cancer Clinical Trials—Reply
Bishal Gyawali, MD, PhD; Elizabeth Eisenhauer, MD; Michael Brundage, MD, MSc
